# EDGAR Filing Document

**Accession Number:** 0000901832
**File Stem:** 0001104659-26-008613
**Filing Date:** 2026-1
**Character Count:** 7433
**Document Hash:** 3ccee57fc87d6e345a455833d4611b2f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-008613.hdr.sgml**: 20260130

**ACCESSION NUMBER**: 0001104659-26-008613

**CONFORMED SUBMISSION TYPE**: 25

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260130

**DATE AS OF CHANGE**: 20260130

**EFFECTIVENESS DATE**: 20260130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASTRAZENECA PLC
- **CENTRAL INDEX KEY:** 0000901832
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 25
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-11960
- **FILM NUMBER:** 26583250

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA
- **BUSINESS PHONE:** 011 44 20 7304 5000

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 FRANCIS CRICK AVENUE
- **STREET 2:** CAMBRIDGE BIOMEDICAL CAMPUS
- **CITY:** CAMBRIDGE
- **PROVINCE COUNTRY:** X0
- **ZIP:** CB2 0AA

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZENECA GROUP PLC
- **DATE OF NAME CHANGE:** 19930422
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AstraZeneca Finance LLC
- **CENTRAL INDEX KEY:** 0001862005
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 25
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40452
- **FILM NUMBER:** 26583251

**BUSINESS ADDRESS:**
- **STREET 1:** 1209 ORANGE STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801
- **BUSINESS PHONE:** 1-800-677-3394

**MAIL ADDRESS:**
- **STREET 1:** 1209 ORANGE STREET
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19801

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 25**

**NOTIFICATION OF REMOVAL FROM LISTING AND/OR<br> REGISTRATION UNDER SECTION 12(b) OF THE<br> SECURITIES EXCHANGE ACT OF 1934.**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**001-11960** | &nbsp;&nbsp;**001-40452** |
| &nbsp;&nbsp;Commission File Number | &nbsp;&nbsp;Commission File Number |
| &nbsp;&nbsp; <br> **AstraZeneca PLC**<br> **The Nasdaq Stock Market LLC** | &nbsp;&nbsp; <br> **AstraZeneca Finance LLC**<br> **The Nasdaq Stock Market LLC** |
| &nbsp;&nbsp;(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) | &nbsp;&nbsp;(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) |
| &nbsp;&nbsp; <br> **1 Francis Crick Avenue**<br> **Cambridge Biomedical Campus**<br> **Cambridge CB2 0AA**<br> **England**<br> **Tel: +44-20-3749-5000** | &nbsp;&nbsp; **1209 Orange Street**<br> **Wilmington, Delaware 19801**<br> **United States of America**<br> **Tel: +1-800-677-3394** |
| &nbsp;&nbsp;(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices) | &nbsp;&nbsp;(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices) |
| &nbsp;&nbsp; <br> **American Depositary Shares, each representing one half of an Ordinary Share of 25¢ each**<br> **Ordinary Shares of 25¢ each**<br> **0.700% Notes due 2026**<br> **1.200% Notes due 2026 (and the guarantee of AstraZeneca PLC related thereto)**<br> **4.800% Notes due 2027 (and the guarantee of AstraZeneca PLC related thereto)**<br> **3.125% Notes due 2027**<br> **4.875% Notes due 2028 (and the guarantee of AstraZeneca PLC related thereto)**<br> **1.750% Notes due 2028 (and the guarantee of AstraZeneca PLC related thereto)**<br> **4.000% Notes due 2029**<br> **4.850% Notes due 2029 (and the guarantee of AstraZeneca PLC related thereto)**<br> **4.900% Notes due 2030 (and the guarantee of AstraZeneca PLC related thereto)**<br> **1.375% Notes due 2030**<br> **4.900% Notes due 2031 (and the guarantee of AstraZeneca PLC related thereto)**<br> **2.250% Notes due 2031 (and the guarantee of AstraZeneca PLC related thereto)**<br> **4.875% Notes due 2033 (and the guarantee of AstraZeneca PLC related thereto)**<br> **5.000% Notes due 2034 (and the guarantee of AstraZeneca PLC related thereto)**<br> **6.450% Notes due 2037**<br> **4.000% Notes due 2042**<br> **4.375% Notes due 2045**<br> **4.375% Notes due 2048**<br> **2.125% Notes due 2050**<br> **3.000% Notes due 2051** | &nbsp;&nbsp; <br> **American Depositary Shares, each representing one half of an Ordinary Share of 25¢ each**<br> **Ordinary Shares of 25¢ each**<br> **0.700% Notes due 2026**<br> **1.200% Notes due 2026 (and the guarantee of AstraZeneca PLC related thereto)**<br> **4.800% Notes due 2027 (and the guarantee of AstraZeneca PLC related thereto)**<br> **3.125% Notes due 2027**<br> **4.875% Notes due 2028 (and the guarantee of AstraZeneca PLC related thereto)**<br> **1.750% Notes due 2028 (and the guarantee of AstraZeneca PLC related thereto)**<br> **4.000% Notes due 2029**<br> **4.850% Notes due 2029 (and the guarantee of AstraZeneca PLC related thereto)**<br> **4.900% Notes due 2030 (and the guarantee of AstraZeneca PLC related thereto)**<br> **1.375% Notes due 2030**<br> **4.900% Notes due 2031 (and the guarantee of AstraZeneca PLC related thereto)**<br> **2.250% Notes due 2031 (and the guarantee of AstraZeneca PLC related thereto)**<br> **4.875% Notes due 2033 (and the guarantee of AstraZeneca PLC related thereto)**<br> **5.000% Notes due 2034 (and the guarantee of AstraZeneca PLC related thereto)**<br> **6.450% Notes due 2037**<br> **4.000% Notes due 2042**<br> **4.375% Notes due 2045**<br> **4.375% Notes due 2048**<br> **2.125% Notes due 2050**<br> **3.000% Notes due 2051** |
| &nbsp;&nbsp;(Description of class of securities) | &nbsp;&nbsp;(Description of class of securities) |

---

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

◻ 17 CFR 240.12d2-2(a)(1)

◻ 17 CFR 240.12d2-2(a)(2)

◻ 17 CFR 240.12d2-2(a)(3)

◻ 17 CFR 240.12d2-2(a)(4)

◻ Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.

⌧ Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, each of AstraZeneca PLC and AstraZeneca Finance LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
|  | **ASTRAZENECA PLC** | **ASTRAZENECA PLC** |
| Date: January 30, 2026 | By: | /s/ Matthew Bowden |
|  |  | Name: Matthew Bowden |
|  |  | Title: Company Secretary |

---

---

| | | |
|:---|:---|:---|
|  | **ASTRAZENECA FINANCE LLC** | **ASTRAZENECA FINANCE LLC** |
| Date: January 30, 2026 | By: | /s/ Mike Elloian |
|  |  | Name: Mike Elloian |
|  |  | Title: Director |

---